What goes wrong in the brain in Alzheimer’s disease is one of the great mysteries of medicine. New research out of MIT may shed light on the problem. CNBC's Meg Tirrell reports the latest.
CNBC's Meg Tirrell reports the latest on Regeneron Pharmaceuticals getting FDA approval for potentially an important drug.
NEW YORK, March 20- Trading in Sprouts Farmers Market Inc's shares and options surged last week ahead of a report that the natural-foods retailer was the subject of merger talks, raising questions about whether news of a possible deal was leaked. On Sunday, Bloomberg reported that the Cerberus Capital- backed food and drug retailer Albertsons Cos had held...
There's a major advancement in fighting heart disease, but the new drug behind it is not cheap. CNBC's Meg Tirrell reports the latest on this cholesterol drug from Amgen.
CNBC's Eamon Javers reports on the outcome of President Trump's meeting with on Rep. Elijah Cummings (D-Maryland) over prescription drug pricing, as well as the president's meeting with business leaders on infrastructure.
Rep. Elijah Cummings (D-Maryland) makes remarks after meeting with President Trump over prescription drug pricing, African American communities and voter fraud. With Rep. Peter Welch (D-Vermont).
CNBC's Jim Cramer weighs in on Mylan and CEO Heather Bresch.
CNBC's Brian Sullivan asks Mylan CEO Heather Bresch about the company's outperformance relative to its peers.
Mylan CEO Heather Bresch discusses the company's progress from its EpiPen firestorm.
David Ricks, Eli Lilly CEO, weighs in on tax reform priorities, border adjustment tax and drug pricing.
Feb 22- CVS Health Corp said its pharmacy chain had removed artificial trans fats, which have been linked to rising rates of heart diseases, from its store-branded food products well ahead of a June 2018 federal deadline. The U.S. Food and Drug Administration said in June 2015 that PHOs were not "generally recognized as safe" for use in human food and gave food...
CNBC's Jim Cramer and David Faber weigh in on Carl Icahn stepping up the pressure on Bristol-Myers.
Chester Davis, Association for Accessible Medicines CEO weighs in on highly-priced generic drugs.
CNBC's Meg Tirrell reports the latest on how the fight over drug prices has sparked a civil war in the pharmaceutical industry, with big branded companies in one corner and the generics in the other.
Dave Dorman, CVS Health non-excutive chairman and former AT&T chairman & CEO, discusses the issues around drug pricing and pharmaceutical companies.
Discussing the potential downside to pharmaceutical companies developing cures with Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy, and Brian Skorney, Baird biotechnology analyst. CNBC's Meg Tirrell also weighs in.
CNBC's Meg Tirrell reports on Gilead's new drug that cures Hepatitis C.
Feb 9- Drugstore chain and pharmacy benefits manager CVS Health Corp reported an 11.7 percent rise in quarterly revenue on Thursday, helped by strength in its PBM business. Net income attributable to CVS rose to $1.71 billion, or $1.59 per share, in the fourth quarter ended Dec. 31, from about $1.50 billion, or $1.34 per share, a year earlier. Revenue rose to $45.97...
The new terms set shares of Rite Aid at a maximum of $7 per share and $6.50 minimum, down from the initial $9 Walgreens agreed to purchase.
Novo Nordisk is investing 115 million pounds in a new research center in Britain, undeterred by Brexit.